UAB O’Neal Cancer Center shared on LinkedIn:
“The management of chronic myeloid leukemia (CML) has undergone a remarkable evolution, driven by advances in targeted therapy, molecular diagnostics, and a deeper understanding of disease biology.
In a recent OncoDaily TV, Jorge Cortes, deputy director of UAB O’Neal Cancer Center discusses the evolution of CML treatment and the increasingly sophisticated approaches to disease monitoring and therapeutic decision-making.
The conversation highlights how contemporary strategies are moving beyond disease control toward deeper molecular responses and the possibility of treatment-free remission for selected patients.
An important discussion on the progress of CML research and the continued evolution of precision oncology.
View the article ‘The CML Evolution: Mastering Modern Algorithms in Chronic Myeloid Leukemia‘ to hear Dr. Cortes discuss where CML treatment has been and where it is headed at the following link.”
